91 related articles for article (PubMed ID: 29802706)
1. Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis.
Liang ZG; Lin GX; Ye JX; Li Y; Li L; Qu S; Liang X; Zhu XD
Asian Pac J Cancer Prev; 2018 May; 19(5):1397-1404. PubMed ID: 29802706
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.
Yang Z; Zuo Q; Liu R; Wu H; Xiong L; Jia J; Xiang Z
BMC Cancer; 2023 Nov; 23(1):1140. PubMed ID: 37996813
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma.
Xu G; Wang Q; Wu X; Lv C; Zeng G; Xue Z; Cao R; Zhang N; Xiong W; Huang Q
Technol Cancer Res Treat; 2021; 20():1533033821990017. PubMed ID: 33511908
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case-control study.
Wu X; Huang J; Liu L; Li H; Li P; Zhang J; Xie L
Medicine (Baltimore); 2016 Sep; 95(39):e4926. PubMed ID: 27684830
[TBL] [Abstract][Full Text] [Related]
5. Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma.
Li Z; Li Y; Yan S; Fu J; Zhou Q; Huang X; Shen L
Onco Targets Ther; 2017; 10():5445-5458. PubMed ID: 29180878
[TBL] [Abstract][Full Text] [Related]
6. Comparing outcomes of concurrent chemotherapy regimens in patients 65 years old or older with locally advanced oropharyngeal carcinoma.
Amini A; Eguchi M; Jones BL; Stokes WA; Gupta A; McDermott JD; Massarelli E; Bradley CJ; Karam SD
Cancer; 2018 Nov; 124(22):4322-4331. PubMed ID: 30291789
[TBL] [Abstract][Full Text] [Related]
7. Treatment Protocols in the Efficacy and Safety of Anti-EGFR Medicines in Combination with Standard Therapy for Patients with Nasopharyngeal Cancer: A Meta-Analysis.
Fang Y; Fan J; Yan C
Biomed Res Int; 2023; 2023():9477442. PubMed ID: 36794258
[TBL] [Abstract][Full Text] [Related]
8. Combining Nimotuzumab With Chemotherapy for Patients With Locally Advanced and Intermediate-Stage Nasopharyngeal Cancer: A Retrospective Comparison Study Using Five-Year, Real-World Survival Data.
Rachman A; Sari SR; Munandar A; Adham M; Hutajulu SH
Cureus; 2023 Nov; 15(11):e48804. PubMed ID: 38098929
[TBL] [Abstract][Full Text] [Related]
9. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study.
Niu X; Liu P; Zhou X; Ou D; Wang X; Hu C
Transl Oncol; 2024 Jan; 39():101797. PubMed ID: 37865048
[TBL] [Abstract][Full Text] [Related]
10. Nutritional intervention for the prognosis of nasopharyngeal carcinoma chemoradiotherapy patients: A meta-analysis.
He Y; Chen X; Yang T; Li Y; Tan S; Liu X
Medicine (Baltimore); 2023 Oct; 102(41):e35386. PubMed ID: 37832079
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma.
Wang F; Jiang C; Ye Z; Sun Q; Liu T; Xu M; Wu P; Shi K; Long B; Fu Z; Jiang Y
Transl Oncol; 2018 Apr; 11(2):338-345. PubMed ID: 29425953
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis.
Zheng B; He M; Han Y; Jiang X; Ou X; Zhang P; Guo R; Li J; Zhang X; Qiao Q; Wu H; Hu M; Feng M; Tu W; Yi J
Curr Cancer Drug Targets; 2024 Feb; ():. PubMed ID: 38549541
[TBL] [Abstract][Full Text] [Related]
13. High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis.
Sun X; Wang L; Wang Y; Kang J; Jiang W; Men Y; Hui Z
Front Oncol; 2020; 10():1222. PubMed ID: 32850362
[No Abstract] [Full Text] [Related]
14. Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: A meta-analysis.
Ding X; Cui X; Cui X; Wang S
Radiother Oncol; 2023 Nov; 188():109860. PubMed ID: 37625701
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis.
Sun X; Zhu Y; Lou Y; Lu X; Wang B; Yu D; Guo Y; Xin Y
Eur Arch Otorhinolaryngol; 2024 Apr; ():. PubMed ID: 38625559
[TBL] [Abstract][Full Text] [Related]
16. Platinum-crosslinking polymeric nanoparticle for synergetic chemoradiotherapy of nasopharyngeal carcinoma.
Ding Y; Xiao X; Zeng L; Shang Q; Jiang W; Xiong S; Duan X; Shen J; Wang R; Guo J; Pan Y
Bioact Mater; 2021 Dec; 6(12):4707-4716. PubMed ID: 34095627
[TBL] [Abstract][Full Text] [Related]
17. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGFR therapies in nasopharyngeal carcinoma.
Chen X; Liang R; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110649. PubMed ID: 32836074
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab Plus Concurrent Radiotherapy in Patients With Nasopharyngeal Carcinoma.
Yamauchi M; Sato Y; Ishida T; Minesaki A; Shimazaki E; Kuratomi Y
In Vivo; 2023; 37(5):2224-2228. PubMed ID: 37652522
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
